Opendata, web and dolomites

TRANSCAN-2 SIGNED

ERA-NET: Aligning national/regional translational cancer research programmes and activities

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "TRANSCAN-2" data sheet

The following table provides information about the project.

Coordinator
MINISTERO DELLA SALUTE 

Organization address
address: Via Giorgio Ribotta 5
city: ROMA
postcode: 144
website: www.salute.gov.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.transcanfp7.eu
 Total cost 22˙568˙750 €
 EC max contribution 6˙672˙187 € (30%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-HCO-2014
 Funding Scheme ERA-NET-Cofund
 Starting year 2015
 Duration (year-month-day) from 2015-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MINISTERO DELLA SALUTE IT (ROMA) coordinator 1˙007˙459.00
2    BUNDESMINISTERIUM FUER BILDUNG UND FORSCHUNG DE (BONN) participant 1˙007˙459.00
3    INSTITUT NATIONAL DU CANCER GIP FR (BOULOGNE BILLANCOURT) participant 532˙429.00
4    FONDS ZUR FÖRDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG AT (WIEN) participant 374˙086.00
5    STICHTING KONINGIN WILHELMINA FONDS VOOR DE NEDERLANDSE KANKERBESTRIJDING NL (AMSTERDAM) participant 374˙086.00
6    TURKIYE BILIMSEL VE TEKNOLOJIK ARASTIRMA KURUMU TR (ANKARA) participant 310˙749.00
7    FONDATION ARC POUR LA RECHERCHE SUR LE CANCER FR (VILLEJUIF) participant 215˙743.00
8    INSTITUTO DE SALUD CARLOS III ES (MADRID) participant 215˙743.00
9    MINISTERO DELL'ISTRUZIONE, DELL'UNIVERSITA' E DELLA RICERCA IT (ROMA) participant 215˙743.00
10    NARODOWE CENTRUM BADAN I ROZWOJU PL (WARSZAWA) participant 215˙743.00
11    NORGES FORSKNINGSRAD NO (OSLO) participant 215˙743.00
12    Kreftforeningen NO (OSLO) participant 215˙742.00
13    Ministrstvo za izobrazevanje, znanost in sport SI (Ljubljana) participant 199˙908.00
14    FUNDACAO PARA A CIENCIA E A TECNOLOGIA PT (LISBOA) participant 160˙322.00
15    FUNDACION PARA EL FOMENTO EN ASTURIAS DE LA INVESTIGACION CIENTIFICA APLICADA Y TECNOLOGIA ES (OVIEDO) participant 152˙405.00
16    VALSTS IZGLITIBAS ATTISTIBAS AGENTURA LV (RIGA) participant 152˙405.00
17    ZORGONDERZOEK NEDERLAND ZON NL (DEN HAAG) participant 152˙405.00
18    ALLEANZA CONTRO IL CANCRO IT (ROMA) participant 136˙571.00
19    MINISTRY OF HEALTH IL (JERUSALEM) participant 133˙404.00
20    SLOVENSKA AKADEMIA VIED SK (BRATISLAVA) participant 123˙904.00
21    FONDS DE LA RECHERCHE SCIENTIFIQUE- FNRS BE (BRUXELLES) participant 120˙737.00
22    FONDS VOOR WETENSCHAPPELIJK ONDERZOEK-VLAANDEREN BE (BRUSSEL) participant 120˙737.00
23    SIHTASUTUS EESTI TEADUSAGENTUUR EE (TARTU) participant 89˙068.00
24    DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV DE (KOELN) participant 57˙399.00
25    GENIKI GRAMMATIA EREVNAS KAI TECHNOLOGIAS EL (ATHENS) participant 57˙399.00
26    ISTITUTO SUPERIORE DI SANITA IT (ROMA) participant 57˙399.00
27    Orszagos Onkologiai Intezet HU (Budapest) participant 57˙399.00
28    LATVIJAS ZINATNU AKADEMIJA LV (RIGA) participant 0.00
29    MINISTRY OF SCIENCE AND TECHNOLOGY TW (Taipei) participant 0.00

Map

 Project objective

Cancer is a worldwide health burden and represents a major public health challenge in Europe. It is responsible for 25% of all deaths, being the second most common cause of death after cardio-vascular diseases and the main cause of mortality among people aged 45–64. Today, an estimated 9 million individuals in Europe live with cancer (Globocan 2008, http://globocan.iarc.fr/). Cancer became a chronic disease which contributed substantially to the growth of medical expenditures and constitutes a major socio-economic challenge for Europe as well as globally. A rapid and effective bidirectional transfer of relevant cancer research findings between bench and bedside would play a pivotal role in addressing top-priority needs at the EU level to reduce incidence and mortality of malignancies and to improve the quality of life of cancer patients. The proposed ERA-NET Cofund TRANSCAN-2, in continuity with the preceding and ongoing TRANSCAN ERA-NET, aims at linking translational cancer research funding programmes in 15 Member States, 3 Associated Countries, and a third country. By concentrating transnational resources, TRANSCAN-2 will provide a critical financial and scientific mass for tackling large-scale problems, relevant for improving translational cancer research globally. A co-funded joint transnational call (JTC) will be launched focusing on the topic “Intratumour heterogeneity in resistance to therapy and recurrence” followed by three additional JTCs that will be implemented in a frame of multinational translational cancer research programmes. In addition, strategies will be developed for the enlargement of the network, for improvement of coordination and for an efficient communication and dissemination of the results of the consortium as well as of the research projects funded through the JTCs. The monitoring of the projects funded through the JTCs and the critical assessment of the performance of TRANSCAN-2, based on key indicators, will be also realised.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRANSCAN-2" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRANSCAN-2" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More